DBV Technologies Past Earnings Performance
Past criteria checks 0/6
DBV Technologies has been growing earnings at an average annual rate of 19.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 17.6% per year.
Key information
19.5%
Earnings growth rate
40.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -17.6% |
Return on equity | -51.9% |
Net Margin | -462.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial
Sep 21DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M
Aug 01DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty
Jul 07DBV Technologies reports change in U.S. reporting status, cuts headcount
Jan 07DBV Technologies CSO Hugh Sampson to step down from role
Nov 24DBV Technologies shares rockets 85% as EMA approves Viaskin Peanut application
Nov 02Revenue & Expenses BreakdownBeta
How DBV Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 16 | -73 | 32 | 60 |
30 Sep 23 | 6 | -101 | 31 | 77 |
30 Jun 23 | 5 | -101 | 29 | 78 |
31 Mar 23 | 4 | -100 | 26 | 79 |
31 Dec 22 | 5 | -96 | 26 | 76 |
30 Sep 22 | 9 | -71 | 24 | 58 |
30 Jun 22 | 8 | -77 | 29 | 59 |
31 Mar 22 | 5 | -85 | 32 | 60 |
31 Dec 21 | 6 | -98 | 35 | 70 |
30 Sep 21 | 2 | -124 | 39 | 85 |
30 Jun 21 | 4 | -131 | 38 | 94 |
31 Mar 21 | 9 | -148 | 37 | 96 |
31 Dec 20 | 11 | -160 | 45 | 102 |
30 Sep 20 | 17 | -161 | 54 | 100 |
30 Jun 20 | 16 | -171 | 63 | 102 |
31 Mar 20 | 16 | -169 | 74 | 110 |
31 Dec 19 | 15 | -172 | 75 | 111 |
30 Sep 19 | 12 | -176 | 77 | 112 |
30 Jun 19 | 13 | -198 | 90 | 122 |
31 Mar 19 | 13 | -191 | 87 | 119 |
31 Dec 18 | 13 | -190 | 87 | 120 |
30 Sep 18 | 11 | -178 | 77 | 117 |
30 Jun 18 | 11 | -172 | 68 | 118 |
31 Mar 18 | 11 | -182 | 69 | 126 |
31 Dec 17 | 12 | -177 | 64 | 124 |
30 Sep 17 | 11 | -169 | 63 | 119 |
30 Jun 17 | 11 | -157 | 61 | 109 |
31 Mar 17 | 9 | -135 | 54 | 91 |
31 Dec 16 | 8 | -121 | 51 | 81 |
30 Sep 16 | 8 | -109 | 47 | 72 |
30 Jun 16 | 8 | -88 | 39 | 59 |
31 Mar 16 | 8 | -72 | 31 | 50 |
31 Dec 15 | 7 | -49 | 20 | 36 |
30 Sep 15 | 6 | -40 | 16 | 31 |
30 Jun 15 | 6 | -30 | 11 | 25 |
31 Mar 15 | 5 | -27 | 9 | 24 |
31 Dec 14 | 6 | -29 | 10 | 25 |
30 Sep 14 | 6 | -30 | 10 | 27 |
30 Jun 14 | 7 | -32 | 11 | 28 |
31 Mar 14 | 6 | -28 | 11 | 24 |
31 Dec 13 | 5 | -27 | 9 | 24 |
30 Sep 13 | 4 | -23 | 8 | 20 |
30 Jun 13 | 4 | -20 | 7 | 17 |
Quality Earnings: DBVT is currently unprofitable.
Growing Profit Margin: DBVT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DBVT is unprofitable, but has reduced losses over the past 5 years at a rate of 19.5% per year.
Accelerating Growth: Unable to compare DBVT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DBVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: DBVT has a negative Return on Equity (-51.88%), as it is currently unprofitable.